EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of batroxobin on the antithrombotic system in patients with cerebral venous thrombosis: Clues to mechanisms

Duo Lan, Baolian Jiao, Siying Song, Mengqi Wang iD, Xiaoming Zhang, Xiangqian Huang, Yibing Guo, Yuchuan Ding iD, Xunming Ji, Ran Meng iD

CNS Neuroscience & Therapeutics · 2024

DOI: 10.1111/cns.14861 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Duo Lan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Batroxobin, Intracranial Thrombosis, Venous Thrombosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nature Science Foundation of China, Beijing Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose More evidence supports the benefits of batroxobin combined with anticoagulation in correcting acute cerebral venous thrombosis (CVT). The dynamic fluctuations of peripheral blood platelets, fibrinolysis, and coagulation biomarkers during this therapy were analyzed.

Methods

We investigated batroxobin's effects on the antithrombotic system under two regimens. The pretreatment group included patients on anticoagulants for at least 1 week before starting batroxobin. The simultaneous treatment group began both treatments upon admission. The control group received only anticoagulation. Batroxobin was given on alternate days at doses of 10BU, 5BU, and 5BU, totaling three doses. Anticoagulation was continuous. Baseline data were T0; the next day after each batroxobin dose was T1, T2, and T3. Data from these four time points was analyzed.

Results

The time‐point paired sample T‐test results of the pretreatment group [n = 60; mean age (SD), 43.3(16.5); 38 (63.35%) women] showed that batroxobin significantly inhibited ADP‐induced platelet aggregation rate (T1–T0: p = 0.015; T2–T0: p = 0.025; T3–T0: p = 0.013), decreased fibrinogen level (T1–T0: p < 0.001; T2–T0: p < 0.001; T3–T0: p < 0.001), and increased D‐dimer (T1–T0: p < 0.001; T2–T0: p < 0.001; T3–T0: p < 0.001), TT (T1–T0: p = 0.046; T2–T0: p = 0.003; T3–T0: p < 0.001), and APTT (T1–T0: p = 0.021; T2–T0: p = 0.012; T3–T0: p = 0.026). Compared to the control group, the simultaneous treatment group showed significantly higher TT (T2: p = 0.002; T3: p = 0.004) and D‐dimer (T1: p < 0.001; T2: p < 0.001; T3: p < 0.001) values, while fibrinogen (T2: p < 0.001; T3: p < 0.001) levels were significantly lower. Using batroxobin can alleviate the amplitude of changes in coagulation indicators other than TT caused by anticoagulants. The above conclusions are consistent with the results of repeated measurement data analysis.

Conclusions

Batroxobin can significantly inhibit ADP‐induced platelet aggregation rate, increase D‐dimer, decrease fibrinogen, and prolong TT and APTT in the presence of anticoagulant agents. Using batroxobin can reduce the amplitude of changes in coagulation indicators caused by anticoagulants. These results reveal the potential mechanism of batroxobin combined with anticoagulation in the safe and effective treatment of CVT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BatroxobinIntracranial ThrombosisVenous ThrombosisHumansMaleFemaleMiddle AgedAdultFibrinolytic AgentsPlatelet AggregationAnticoagulantsFibrin Fibrinogen Degradation ProductsAgedBlood Platelets

Stichwörter der Autor:innen

antithrombusbatroxobincoagulationfibrinolysisplatelet aggregation

Substanzen

BatroxobinFibrinolytic AgentsAnticoagulantsFibrin Fibrinogen Degradation Productsfibrin fragment D

Autor:innen und Institutionen

  • Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Department of China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Division of Neurocritical Care and Emergency Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Neurosurgery, Wayne State University School of Medicine, Detroit, Michigan, USA.

ORCID-Profile: Mengqi Wang, Yuchuan Ding, Ran Meng

Förderung

  • National Nature Science Foundation of China
  • Beijing Natural Science Foundation
  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Lan, D., Jiao, B., Song, S., Wang, M., Zhang, X., Huang, X., Guo, Y., Ding, Y., Ji, X., & Meng, R. (2024). Effects of batroxobin on the antithrombotic system in patients with cerebral venous thrombosis: Clues to mechanisms. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14861

Vancouver

Lan D, Jiao B, Song S, Wang M, Zhang X, Huang X, et al. Effects of batroxobin on the antithrombotic system in patients with cerebral venous thrombosis: Clues to mechanisms. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14861

BibTeX
@article{Lan2024,
  author = {Lan, Duo and Jiao, Baolian and Song, Siying and Wang, Mengqi and Zhang, Xiaoming and Huang, Xiangqian and Guo, Yibing and Ding, Yuchuan and Ji, Xunming and Meng, Ran},
  title = {Effects of batroxobin on the antithrombotic system in patients with cerebral venous thrombosis: Clues to mechanisms},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  doi = {10.1111/cns.14861}
}
Kostenlos starten →